share_log

MEDIROM Healthcare Technologies | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

MEDIROM Healthcare Technologies | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

MEDIROM Healthcare Technologies | 6-K：外国发行人报告
美股SEC公告 ·  2024/10/15 03:17

Moomoo AI 已提取核心信息

MEDIROM MOTHER Labs Inc. (MML), a subsidiary of MEDIROM Healthcare Technologies, has entered into a capital and business alliance agreement with Elematec Corporation on October 15, 2024. Elematec will invest JPY100.08 million by purchasing 556 series A preferred shares at JPY180,000 per share, valuing MML at JPY9 billion pre-money.Under the agreement, Elematec will become the exclusive outsourcing partner for procurement and manufacturing of MML's recharge-free wearable devices, including the MOTHER Bracelet 2.0 and MOTHER Gateway. Elematec will also gain non-exclusive sales rights for MOTHER Bracelets and first-offer rights for future generation devices.The agreement includes provisions for share repurchase at the higher of the original price or fair value if terminated. The deal's closing is subject to conditions including satisfactory intellectual property reports. MML's CEO Kouji Eguchi and Representative Director Yoshio Uekusa have committed to dedicated involvement and non-compete obligations for the business.
MEDIROM MOTHER Labs Inc. (MML), a subsidiary of MEDIROM Healthcare Technologies, has entered into a capital and business alliance agreement with Elematec Corporation on October 15, 2024. Elematec will invest JPY100.08 million by purchasing 556 series A preferred shares at JPY180,000 per share, valuing MML at JPY9 billion pre-money.Under the agreement, Elematec will become the exclusive outsourcing partner for procurement and manufacturing of MML's recharge-free wearable devices, including the MOTHER Bracelet 2.0 and MOTHER Gateway. Elematec will also gain non-exclusive sales rights for MOTHER Bracelets and first-offer rights for future generation devices.The agreement includes provisions for share repurchase at the higher of the original price or fair value if terminated. The deal's closing is subject to conditions including satisfactory intellectual property reports. MML's CEO Kouji Eguchi and Representative Director Yoshio Uekusa have committed to dedicated involvement and non-compete obligations for the business.
MEDIROm MOTHER Labs Inc. (MML)是MEDIROm Healthcare Technologies的子公司，于2024年10月15日与Elematec Corporation签署了一项资本和业务联盟协议。Elematec将通过每股180,000日元购买556股A系列优先股，投资10008万日元，MML的估值为90亿日元（未入账）。根据协议，Elematec将成为MML免充电可穿戴设备（包括MOTHER Bracelet 2.0和MOTHER Gateway）采购和制造的独家外包合作伙伴。Elematec还将获得MOTHER Bracelets的非独占销售权以及未来代际设备的优先购买权。该协议包括在终止时以原价或公平价值更高者的条件进行股份回购的条款。交易的完成需满足包括知识产权报告满意在内的条件。MML的首席执行官江口浩司和代表董事上草义夫承诺将专注于业务进行参与及不竞争义务。
MEDIROm MOTHER Labs Inc. (MML)是MEDIROm Healthcare Technologies的子公司，于2024年10月15日与Elematec Corporation签署了一项资本和业务联盟协议。Elematec将通过每股180,000日元购买556股A系列优先股，投资10008万日元，MML的估值为90亿日元（未入账）。根据协议，Elematec将成为MML免充电可穿戴设备（包括MOTHER Bracelet 2.0和MOTHER Gateway）采购和制造的独家外包合作伙伴。Elematec还将获得MOTHER Bracelets的非独占销售权以及未来代际设备的优先购买权。该协议包括在终止时以原价或公平价值更高者的条件进行股份回购的条款。交易的完成需满足包括知识产权报告满意在内的条件。MML的首席执行官江口浩司和代表董事上草义夫承诺将专注于业务进行参与及不竞争义务。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Bright Horizons Family Solutions
    BFAM
    -- 128.930
    力奇服务
    CLIK
    -- 1.195
    Regis
    RGS
    -- 23.950
    Interactive Strength
    TRNR
    -- 1.310
    YY Group
    YYGH
    -- 1.823
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。